Certify Before You Buy—How To Deal With New Machinery

Derek DeGeest, President of DeGeest Corporation and LestaUSA, knows when the industry comes together to help each other, successful integration of robotics and automation into operations follows. After being on both sides of the coin of installing a large finishing system and shepherding in new self-learning robotic technology to North America, it’s important to share the combined experiences of DeGeest Corp and LestaUSA to help manufacturing grow.

DeGeest wants to encourage other general industry manufacturers to bring new machinery into their operations. But, there is also a cautionary tale to be told. DeGeest shared his company’s ulcer-inducing experience and learnings when, as a contract job shop, they installed a large finishing system. A new state regulatory interpretation on machinery vs equipment almost shut down the entire system.

Without certification, the machinery was useless. “We had to find a way to learn the regulatory system and work with every group to find a solution,” DeGeest said. “And we did. Fast forward, three years later, we now have the largest robotic painting system in the contract job shop world in North America.”

DeGeest also walks through the process of getting Lesta’s robot technology NRTL certified and the importance of having this certification in North America. Launching Lesta’s proven robotic system’s in North America proved to need a different set of classifications than European standards that required multiple system changes.

DeGeest recognized when dealing with new machinery and equipment in the marketplace; regulators have an impossible task. “Changing technology in manufacturing is so fast that it doesn’t keep up with the code, and it is hard for them (the regulators) to interpret how they’re supposed to apply that to the new machinery that’s coming out,” DeGeest said. “That’s what happened to us. Our machinery was newly interpreted as equipment according to the codebook, so they didn’t know what to do.” DeGeest worked with the regulators to hammer out a solution, rewrite the code, and create a path forward for other industry companies. Why? Because at DeGeest Corporation and Lesta USA, they believe a rising tide lifts all boats.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More